University of Louisville researchers' technology could block the coronavirus from infecting human cells
Researchers at the University of Louisville have joined the coronavirus treatment and prevention fray, announcing Wednesday they believe a technology they developed could block the virus from infecting human cells.
It's based on a piece of synthetic DNA (also known as an aptamer) which targets and binds with a human protein called nucleolin. Early research and experiments, led by researchers Paula Bates, John Trent, and Don Miller, indicate the aptamer may be effective at preventing the coronavirus from "hijacking" nucleolin to replicate inside the body at doses previously shown to be safe in patients. The Louisville team has applied the same aptamer in a variety of ways, and it has reportedly emerged as a potential therapeutic drug for multiple types of cancer.
The university is trying to develop the potential treatment as quickly as possible, including sending an application to the Food and Drug Administration for approval to begin treating patients suffering severe cases of COVID-19.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
There are currently no known treatments for COVID-19, though scientists around the world are conducting tests on multiple potential therapies.
Create an account with the same email registered to your subscription to unlock access.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Tim is a staff writer at The Week and has contributed to Bedford and Bowery and The New York Transatlantic. He is a graduate of Occidental College and NYU's journalism school. Tim enjoys writing about baseball, Europe, and extinct megafauna. He lives in New York City.
-
What to know when planning an awe-inspiring hike on the Inca Trail
The Week Recommends Peru's most famous trail leads to Machu Picchu
By Catherine Garcia, The Week US Published
-
Lead poisoning remains a threat
The Explainer The toxin is built into our lives
By Devika Rao, The Week US Published
-
Should you use a 529 plan? What to know about this college savings option.
The Explainer This tax-advantaged savings account can be used to pay tuition or buy textbooks
By Becca Stanek, The Week US Published
-
Texas dairy worker gets bird flu from infected cow
Speed Read The virus has been spreading among cattle in Texas, Kansas, Michigan and New Mexico
By Peter Weber, The Week US Published
-
Dengue hits the Americas hard and early
Speed Read Puerto Rico has declared an epidemic as dengue cases surge
By Peter Weber, The Week US Published
-
Covid four years on: have we got over the pandemic?
Today's Big Question Brits suffering from both lockdown nostalgia and collective trauma that refuses to go away
By Chas Newkey-Burden, The Week UK Published
-
US bans final type of asbestos
Speed Read Exposure to asbestos causes about 40,000 deaths in the U.S. each year
By Peter Weber, The Week US Published
-
The hollow classroom
Opinion Remote school let kids down. It will take much more than extra tutoring for kids to recover.
By Mark Gimein Published
-
Excess screen time is making children only see what is in front of them
Under the radar The future is looking blurry. And very nearsighted.
By Devika Rao, The Week US Published
-
Covid-19: what to know about UK's new Juno and Pirola variants
in depth Rapidly spreading new JN.1 strain is 'yet another reminder that the pandemic is far from over'
By Arion McNicoll, The Week UK Published
-
Long-term respiratory illness is here to stay
The Explainer Covid is not the only disease with a long version
By Devika Rao, The Week US Published